# FDA Approves Veppanu for HR-Positive HER2-Negative ESR1-Mutated Advanced Breast Cancer

> fda · REPORTED · 2026-06-30

The FDA approved vepdegestrant (Veppanu) for patients with hormone receptor-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer, reflecting the growing trend toward biomarker-driven personalized breast cancer therapies. This approval was among five breast cancer treatment approvals or expansions between May and June 2026.

About Veppanu / Olema Pharmaceuticals (vepdegestrant): Olema Pharmaceuticals is an oncology company developing targeted therapies for breast cancer and other hormone-driven cancers, with vepdegestrant being its lead selective estrogen receptor degrader asset.

- Company: Veppanu / Olema Pharmaceuticals (vepdegestrant)
- Sector: oncology
- Primary source: https://www.vbcf.org/breast-cancer-news-you-can-use-july-2026/

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.